Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its
prevalence is rapidly increasing due to extended lifespans. Among the increasing number of …

There is increasing appreciation that non-neuronal cells contribute to the initiation,
progression and pathology of diverse neurodegenerative disorders. This Review focuses on …

Alzheimer's disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into …

Animal studies show aging varies between individuals as well as between organs within an
individual,,–, but whether this is true in humans and its effect on age-related diseases is …

Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

Most complex human traits differ by sex, but we have limited insight into the underlying
mechanisms. Here, we investigated the influence of biological sex on protein expression …

Several common psychiatric and neurodegenerative diseases share epidemiologic risk;
however, whether they share pathophysiology is unclear and is the focus of our …

Proteomics can shed light on the dynamic and multifaceted alterations in neurodegenerative
disorders like Alzheimer's disease (AD). Combining radioligands measuring β-amyloid (Aβ) …

Alzheimer disease (AD) is associated with multiple etiologies and pathological mechanisms,
among which oxidative stress (OS) appears as a major determinant. Intriguingly, OS arises …